EcoR1 Capital LLC lowered its stake in shares of Prothena Co. PLC (NASDAQ:PRTA) by 0.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 723,300 shares of the biotechnology company’s stock after selling 3,219 shares during the quarter. Prothena makes up approximately 0.8% of EcoR1 Capital LLC’s portfolio, making the stock its 22nd largest holding. EcoR1 Capital LLC owned about 1.81% of Prothena worth $7,645,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. BlackRock Inc. grew its position in Prothena by 0.5% during the second quarter. BlackRock Inc. now owns 3,351,908 shares of the biotechnology company’s stock valued at $35,431,000 after buying an additional 17,619 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Prothena by 34.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,272,832 shares of the biotechnology company’s stock valued at $13,110,000 after acquiring an additional 328,166 shares during the period. Vanguard Group Inc. boosted its position in shares of Prothena by 0.7% in the second quarter. Vanguard Group Inc. now owns 813,376 shares of the biotechnology company’s stock valued at $8,597,000 after acquiring an additional 5,817 shares during the period. Northern Trust Corp boosted its position in shares of Prothena by 7.4% in the second quarter. Northern Trust Corp now owns 520,811 shares of the biotechnology company’s stock valued at $5,504,000 after acquiring an additional 35,777 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Prothena by 59.5% in the second quarter. Jacobs Levy Equity Management Inc. now owns 243,291 shares of the biotechnology company’s stock valued at $2,572,000 after acquiring an additional 90,803 shares during the period. Institutional investors own 96.83% of the company’s stock.
A number of research firms have recently commented on PRTA. Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Wednesday, June 19th. BidaskClub lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 15th. Barclays restated a “sell” rating and issued a $9.00 price objective on shares of Prothena in a research report on Friday, May 31st. Finally, ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Prothena presently has a consensus rating of “Hold” and a consensus target price of $11.26.
PRTA traded down $0.01 on Thursday, reaching $8.55. The company had a trading volume of 6,208 shares, compared to its average volume of 212,880. The business has a 50 day simple moving average of $8.43 and a 200 day simple moving average of $10.21. The company has a market cap of $351.09 million, a price-to-earnings ratio of -2.37 and a beta of 2.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.95 and a current ratio of 14.94. Prothena Co. PLC has a 52-week low of $6.71 and a 52-week high of $14.77.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.16. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.22 million. Prothena had a negative net margin of 10,435.79% and a negative return on equity of 27.59%. As a group, equities research analysts predict that Prothena Co. PLC will post -1.97 EPS for the current fiscal year.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Featured Article: Stock Split
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.